- Home
- INBX vs PIM Comparison
INBX vs PIM Comparison
Compare INBX & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- PIM
- Stock Information
- Founded
- INBX 2010
- PIM 1988
- Country
- INBX United States
- PIM United States
- Employees
- INBX N/A
- PIM N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- PIM Finance Companies
- Sector
- INBX Health Care
- PIM Finance
- Exchange
- INBX Nasdaq
- PIM Nasdaq
- Market Cap
- INBX 168.1M
- PIM 159.3M
- IPO Year
- INBX 2020
- PIM N/A
- Fundamental
- Price
- INBX $11.86
- PIM $3.24
- Analyst Decision
- INBX Hold
- PIM
- Analyst Count
- INBX 1
- PIM 0
- Target Price
- INBX N/A
- PIM N/A
- AVG Volume (30 Days)
- INBX 142.0K
- PIM 57.5K
- Earning Date
- INBX 05-08-2025
- PIM 01-01-0001
- Dividend Yield
- INBX 7.26%
- PIM 8.28%
- EPS Growth
- INBX N/A
- PIM N/A
- EPS
- INBX 112.62
- PIM 0.05
- Revenue
- INBX $200,000.00
- PIM N/A
- Revenue This Year
- INBX N/A
- PIM N/A
- Revenue Next Year
- INBX N/A
- PIM N/A
- P/E Ratio
- INBX $0.10
- PIM $63.80
- Revenue Growth
- INBX N/A
- PIM N/A
- 52 Week Low
- INBX $10.80
- PIM $2.90
- 52 Week High
- INBX $18.95
- PIM $3.28
- Technical
- Relative Strength Index (RSI)
- INBX 41.57
- PIM 46.52
- Support Level
- INBX $11.22
- PIM $3.21
- Resistance Level
- INBX $12.06
- PIM $3.29
- Average True Range (ATR)
- INBX 0.95
- PIM 0.05
- MACD
- INBX -0.11
- PIM 0.00
- Stochastic Oscillator
- INBX 32.99
- PIM 52.63
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.